髓样相关蛋白8／14水平在前列腺癌诊断及预后中的意义  

Analysis of diagnosis and prognosis of MRP8/14 on prostate cancer

作　　者：李娈 张佳[1] 赵丽君[1] 宋雪[1] 邹青[2] 喻彬[2] 余辉[1] 

机构地区：[1]江苏省肿瘤医院肿瘤内科,南京210000 [2]江苏省肿瘤医院泌尿外科,南京210000

出　　处：《中华泌尿外科杂志》2017年第11期848-851,共4页Chinese Journal of Urology

摘　　要：目的探讨髓样相关蛋白8／14（MRP8／14）在前列腺癌诊断及预后判断中的意义。方法回顾性分析2012年10月至2014年10月收治的150例前列腺癌患者的病例资料，年龄（66．4±8．5）岁；150例良性前列腺增生（BPH）患者，年龄（66．8±7．4）岁。根据年龄匹配正常人群150例，年龄（66．5±7．8）岁。采用酶联免疫吸附测定（ELISA）法检测各组受试者血清中MRP8／14的表达情况。采用受试者工作特征曲线（ROC）预测MRP8／14对前列腺癌的诊断价值，根据临界值将前列腺癌患者分为MRP8／14低值组（〈临界值）和MRP8／14高值组（≥临界值），比较两组患者的临床资料和生存情况。结果正常人、BPH患者和前列腺癌患者的MRP8／14水平分别为（966．7±152．8）ng／ml、（1207．0±190．6）ng／ml和（2833．3±1101．5）ng／ml，前列腺癌患者的MRP8／14水平明显高于正常人和BPH患者，差异有统计学意义（P〈0．05）。ROC曲线分析MRP8／14对前列腺癌的诊断价值的曲线下面积（AUC）为0．887（95％C10．841—0．934），差异有统计学意义（P〈0．05）；临界值为2845．7ng／ml，诊断前列腺癌的特异性为76．4％、敏感性为85．1％。MRP8／14低值组88例，MRP8／14高值组62例。与MRP8／14低值组比较，MRP8／14高值组的美国东部肿瘤协作组活动状态1分、Gleason评分8～10分、涉及器官数〉2个和临床肿瘤分期〉m期的患者更多，前列腺特异性抗原（PSA）、乳酸脱氢酶（LDH）、碱性磷酸酶（AKP）、C反应蛋白（CRP）水平更高（P〈0．05）。对前列腺癌患者平均随访2年，32例患者死亡，其中MRP8／14低值组死亡12例，病死率为13．6％；MRP8／14高值组死亡20例，病死率为32．2％。Kaplan—Meier生存函数曲线表明，MRP8／14低值组和MRPS／14高值组的2年生存率分别为86．4％和67．8％，差异有统计学意义（x。=10．403，P〈0．05）。CoObjective To compare the MRP8/14 level in Normal people, benign prostatic hyperplasia（BPH） patient and prostate cancer patient, and explore the relationgship between MRP8/14 and prostate cancer. Methods 150 cases of normal people, 150 cases of BPH patients and 150 cases of prostate cancer patients were chose from December 2012 to December 2014 in our hospital. ELISA method was used to detect the MRP8/14 level in each group. ROC cure was used to analyse the prediction value of MRP8/14 for prostate cancer. According to the cut off value of MRPS/14, prostate cancer patients were divided into MRP8/14 low value group （MRP8/14 〈 cut off value） and MRP8/14 high value group （MRP8/14≥cut off value）, and the difference of patient clinical characteristics and survival function between high value group and low value group were explored. Resplts The MRP8/14 level of normal people was （966. 7 ± 152. 8 ） ng/ml, while the BPH patient was （1 207.0 ± 190. 6） ng/rrd, and the prostate cancer patient was （2 833. 3± 1 101.5）ng/ml, the difference is statistically significant. ROC analysis restxlt showed that the AUC for the prediction of prostate cancer was 0. 887 （ 95% CI O. 841 - 0. 934 ）, with a high statistical significance, indicating that MRPS/14 may possess high prediction value for prostate cancer. In addition, the cut off value was 2 845. 682 ng/ml, with the specifity of 76.4% and sensitivity of 85.1%. According to the cut off value of MRPS/14,prostate cancer patients were divided into the low MRP8/14 group （ 〈 2 845. 682 ng/ml） and the high MRP8/14 group （ I〉2 845. 682 ng/ml）. Among the 150 prostate cancer patients, 88 cases were in the low MRPS/14 group and 62 cases were in the high MRP8/14 group. Comparations of the baseline characteristics of the two groups showed that amount of patients belong to ECOG PS = 1, Gleason score = 8 - 10, organ involvement 〉 2 and tumour stage 〉 M were much more in MRPS/14 high value group. PSA level, LDH level, AKP level, CRP level and Alkalin

关 键 词：髓样相关蛋白8/14 前列腺癌 诊断 临床意义 

分 类 号：R737.25[医药卫生—肿瘤]